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Abstract
Objective—To determine sildenafil exposure and hemodynamic effect in children after stage II
single-ventricle surgery.
Design—Prospective, dose escalation trial.
Setting—Single-center, pediatric catheterization laboratory.
Patients—12 children post stage II single-ventricle surgical palliation and undergoing elective
cardiac catheterization: median age 1.9 years (range: 0.8, 4.0), weight 11 kg (8, 13), 9 females,
and 10 with a single right ventricle.
Interventions—Catheterization and echocardiography performed before and immediately after
single-dose intravenous sildenafil (0.125, 0.25, 0.35, or 0.45 mg/kg over 20 minutes).
Measurements—Peak sildenafil and des-methyl sildenafil concentration, change in
hemodynamic parameters measured by cardiac catheterization and echocardiography including
indexed pulmonary vascular resistance, and myocardial performance.
Main Results—Maximum sildenafil concentrations ranged from 92–775 ng/ml and were above
the in vitro threshold needed for 77% phosphodiesterase type-5 (PDE-5) inhibition in 80% of
subjects and 90% inhibition in 80% of subjects with doses ≥0.35 mg/kg. Sildenafil lowered
pulmonary vascular resistance index (PVRI) in all 12 subjects (median PVRI 2.2 [range: 1.6, 7.9];
decreased to 1.7 [1.2, 5.4] WU x m2; p<0.01) with no dose-response effect. Sildenafil improved
pulmonary blood flow (+8% [0, 20], p=0.04) and saturations (+2% [0, 16], p=0.04) in those with
baseline PVRI ≥2 WU x m2 (n=7). Change in saturations correlated inversely with change in
PVRI (r2 = 0.74 p<0.01). Sildenafil also lowered mean blood pressure (−12% [−20, +10]; p=0.04).
There was no change in cardiac index and no effect on myocardial performance. There were no
adverse events.
Conclusions—Sildenafil demonstrated non-linear exposure with high inter-individual
variability but was well tolerated and effectively lowered PVRI in all subjects. Sildenafil did not
acutely improve myocardial performance or increase cardiac index.
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INTRODUCTION
Staged surgical palliation has markedly improved neonatal outcomes for children with
single-ventricle heart defects.[1] However, operative survivors face ongoing mortality risk
and significant morbidities.[2–5] These consequences are due to the physiologic constraints
of the palliated single-ventricle circulation.[6] In this unique circulation, the 2 principal
determinants of long-term outcome are low pulmonary vascular resistance (PVR) and
adequate single-ventricle myocardial function.[2,5–7] Drugs that lower PVR and/or improve
myocardial performance could optimize circulatory efficiency and potentially improve
outcomes.
Sildenafil is a selective phosphodiesterase type-5 (PDE-5) inhibitor that increases cyclic
guanosine monophosphate and produces vascular smooth muscle relaxation.[8] PDE-5 is
highly expressed in the pulmonary vasculature, and sildenafil is approved by the U.S. Food
and Drug Administration and the European Medicines Agency for treatment of pulmonary
arterial hypertension in adults.[8,9] Emerging data suggest an expanded role for PDE-5
inhibitors in chronic cardiomyopathic states. Benefits including improved systolic and
diastolic performance have been documented in animal models and in adults with heart
failure or ventricular hypertrophy.[10,11] Clinicians have extrapolated these effects to the
single-ventricle population leading to much enthusiasm within the field.[12–14] However,
recent data from the Sildenafil in Treatment-naive Children, Aged 1–17 Years, with
Pulmonary Arterial Hypertension (STARTS) trial have created concerns about sildenafil
safety and efficacy in children. Specifically, efficacy end points were not achieved with low-
dose sildenafil, while there was increased long-term mortality in those treated with high-
dose vs. low-dose sildenafil.[15] These data are particularly relevant to the single-ventricle
population where unique physiology may confound drug response and alter drug
metabolism. No studies to date elucidate the acute hemodynamic effect of PDE-5 inhibition
after single-ventricle palliation, and no studies have evaluated sildenafil pharmacokinetics
(PK) in these patients.
The aim of the present study was to determine intravenous, single-dose sildenafil PK and
hemodynamic effect in patients with single-ventricle heart defects. More specifically, this
analysis focuses on the acute hemodynamic effect and drug exposure correlation after stage
II surgery. Efficacy after stage III surgery and an expanded PK analysis are reported
separately. We hypothesized that sildenafil would acutely improve cardiopulmonary
hemodynamics by lowering pulmonary vascular resistance and improving global myocardial
performance and that improvements in cardiopulmonary hemodynamics would be related to
drug exposure.
MATERIALS AND METHODS
The study was an open-label, prospective, dose escalation trial. The institutional review
board of Duke University Medical Center (Durham, North Carolina) approved the study
protocol. Subjects ≥6 months and ≤10 years of age with single-ventricle heart defects post
stage II surgical palliation and undergoing cardiac catheterization as a part of their routine
clinical care were eligible for participation. Written informed consent was obtained for all
study participants. Exclusion criteria included: 1) history of serious side effects to prior
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sildenafil therapy; 2) history of sildenafil exposure 96 hours prior to the study; 3) pulmonary
venous obstruction; 4) known or suspected pulmonary arterial or cavopulmonary
anastomosis obstruction (catheterization gradient ≥1 mm Hg); 5) known or suspected
coarctation of the aorta (catheterization gradient ≥10 mm Hg); 6) current treatment with
nitrates or alpha blockade medications; and 7) significant renal failure (serum creatinine >2
times higher than the upper limit of normal), thrombocytopenia (platelet count <50,000 ×
106/L) or leukopenia (white blood cell count <2500 grams/dL).
Study protocol
All patients were studied under general anesthesia with mechanical ventilation and a fraction
of inspired oxygen of 0.21. Sedation and ventilation status were kept stable throughout the
hemodynamic portion of the study. Baseline transthoracic echocardiogram and
hemodynamic cardiac catheterization were performed after induction of anesthesia.
Following the initial collection of hemodynamic data, patients were given a single, pre-
determined dose of intravenous (IV) sildenafil (0.125 mg/kg, 0.25 mg/kg, 0.35 mg/kg, or
0.45 mg/kg) over 20 minutes. The initial patients enrolled in the study were assigned to the
lowest dose category with progression to increasing dose levels after reviewing adverse
events for each dose level. Immediately after sildenafil administration, the hemodynamic
catheterization and transthoracic echocardiogram were repeated.
For echocardiograms, a single sonographer performed all studies using a standard cardiac
ultrasound system (Vivid 7®, GE-Vingmed, Horten, Norway). Images were obtained in the
parasternal long, parasternal short, apical, and suprasternal views. Measurements were
performed to assess: diastolic ventricular function (atrioventricular valve inflow E : tissue
Doppler E′ peak velocities), 2D systolic ventricular function (fraction of area change [FAC]
for systemic right ventricles, single-plane modified Simpson’s rule ejection fraction [EF] for
systemic left ventricles), speckle tracking systolic function (strain, strain rate), and global
myocardial performance (myocardial performance index).[16,17] Speckle tracking analysis
was performed offline using Vector Velocity Imaging™ (Siemens Medical Solutions,
Mountain View, CA). Two physicians associated with the study independently performed all
interpretations of the echocardiographic data. Inter-rater reliability was evaluated using
Spearman’s correlation coefficient with r2 values of 0.73, 0.74, 0.84, 0.76, and 0.97 (p<0.05
for all measures) for fractional area change, tissue Doppler E′ to atrioventricular E wave
ratio, strain, strain rate, and myocardial performance index, respectively.
Catheterization assessment included measurement of saturations by co-oximetry including
mixed venous, pulmonary arterial (PA), and systemic arterial oxygen saturations as well as
pressure measurements in the branch pulmonary arteries, common atrium, single ventricle,
and ascending and descending aorta. Pressures were obtained in the standard fashion using
fluid-filled catheters. The PVR, systemic vascular resistance, pulmonary blood flow, and
cardiac output were calculated by the Fick method with oxygen consumption estimated
based on age and heart rate. Blood flow and resistances were indexed to the patient’s body
surface area. For repeat calculations, we used the same estimated oxygen consumption as
was used for baseline measurements, and saturations were sampled from the same locations
as those used at baseline.
PK sampling and analysis
Plasma sildenafil levels were collected immediately following completion of the infusion
(t=25 minutes after initiation of drug infusion). Samples were immediately transferred into
heparinized polypropylene tubes and centrifuged for 5 minutes at 3500 RPM. Samples were
then stored in dry ice and transferred to a −70° C freezer. Sildenafil and des-methyl
sildenafil concentrations were determined using a commercially available assay. The
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quantitative analysis was performed by Covance Laboratories Inc. (Madison, WI) using
high-performance liquid chromatography with tandem mass spectrometry.
Data analysis
The primary hemodynamic outcome measure was change in PVR index (PVRI). Secondary
outcome measures included other hemodynamic variables as well as echocardiographic
measures and exposure response. Statistical analysis included all patients receiving
sildenafil. Demographic data were summarized using descriptive statistics and expressed as
median (range). Change in clinical parameters was expressed as median percent change,
with the exception of change in saturations, which was expressed as absolute change.
Hemodynamic and echocardiographic data were calculated and presented by dosage group.
Standard graphing and screening tests were used to assess for outliers and to determine data
distribution. A Wilcoxon rank sum test was used to compare hemodynamics and
echocardiographic measurements at baseline and after sildenafil administration. Linear
regression was used to examine the correlation between response, dose levels, and
hemodynamic measures expected to affect response. Statistical analysis was performed
using SPSS v. 19.0 software package. A 2-tailed p value <0.05 was considered significant.
RESULTS
Between March 2011 and January 2012, 12 subjects were enrolled. Median (range) age and
weight were 1.9 years (0.8–4.0) and 11.1 kg (8.0–13.2). Nine subjects (75%) were female,
and 10 (83%) had a systemic right ventricle. Table 1 summarizes demographic features and
baseline hemodynamic parameters.
Drug exposure data (Figure 1)
Sildenafil levels peaked immediately after infusion completion, with peak levels ranging
from 92–775 ng/ml. Peak levels for the active metabolite, des-methyl sildenafil ranged from
15–43 ng/ml and were seen between 43 and 117 minutes after peak sildenafil levels. There
was high inter-individual variability (coefficient of variation = 45% for peak sildenafil
levels) and dose non-proportionality with non-linear increase in levels across dosing groups.
Peak PK samples could not be determined for 2 subjects due to processing errors (sample
hemolysis and insufficient plasma volume).
Hemodynamic effect
Sildenafil effect on hemodynamic parameters is shown in Table 2. There was no significant
dose-response effect so data were pooled for assessment of hemodynamic parameters.
Sildenafil lowered PA pressures (−9%, p=0.03), transpulmonary gradient (−23%, p<0.01),
and PVRI (−24%, p<0.01). PVRI was lowered in 12/12 subjects. Linear regression
demonstrated a greater change in PVRI in those with higher baseline PVRI (p<0.01) (Figure
1) but no difference in response based on peak sildenafil (p=0.4) or des-methyl sildenafil
levels (p=0.2). Although there was no overall effect on calculated pulmonary blood flow
(Qp) or saturations, a subgroup analysis of subjects with elevated baseline PVRI (≥2 WU x
m2) (n=7) demonstrated increase in Qp (median change +8%, range 0–20%, p=0.04) and
improved saturations in 6/7 subjects (median absolute change +2%, range 0–16%, p=0.04).
Patients with higher baseline PVRI and those with the greatest change in PVRI experienced
the most meaningful improvements in saturations (r2=0.84, p<0.01 for correlation with
baseline PVRI; r2=0.74, p<0.01 for correlation with change in PVRI) (Figure 2).
Sildenafil affected systemic hemodynamics by lowering systemic mean (−12%, p=0.04) and
diastolic blood pressure (−11%, p<0.01). There was a trend towards lowered systolic blood
pressure (p=0.07) with a noticeable decrease for all 3 subjects in the highest dosing group
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(mean change: −11 ± 2 mm Hg). There was no significant change in cardiac index.
Sildenafil did not affect echocardiographic measures of systolic function (FAC/EF, strain,
strain rate), diastolic function (E:E′ ratio), or global myocardial performance (myocardial
performance index). There was also no significant change in these echocardiographic
indices when restricting the analysis to the subset of 10 patients with a systemic right
ventricle. Sildenafil infusion was well tolerated by all 12 subjects with no adverse events.
DISCUSSION
This is the first prospective study evaluating single-dose sildenafil exposure and
hemodynamic efficacy after stage II surgery. Peak drug levels demonstrated significant
inter-individual variability and dose non-linearity. Sildenafil improved pulmonary
hemodynamics, with lowered PVRI in all 12 subjects and improved oxygen saturation but
with a meaningful improvement seen only in those subjects with higher baseline PVRI.
Sildenafil did not acutely affect multiple measures of myocardial performance.
Despite anecdotal experience and numerous case reports suggesting increasing sildenafil use
in the single-ventricle population, this is the first study to document hemodynamic efficacy
in these patients. Pulmonary blood flow in the single-ventricle circulation is phasic rather
than pulsatile. Phasic flow may contribute to documented endothelial dysfunction and
ultimately elevated pulmonary vascular resistance.[12,18] This pathophysiology is different
from shunt-related or idiopathic PA hypertension, and this difference limits extrapolation of
hemodynamic efficacy from these populations. Furthermore, patients with single-ventricle
physiology require substantially lower PVR than patients with a 2-ventricle circulation. It
was previously unclear whether there might be a “floor effect” on the ability of therapeutic
agents to lower PVRI. Our data demonstrate that sildenafil effectively lowers PVRI across a
wide range of resistances, with responses ranging from 4–38% in patients with baseline
PVRI ranging from 1.6–7.9 WU x m2.
Overall, the clinical impact of sildenafil after stage II palliation is less clear. In the stage II
circulation, pulmonary blood flow must first pass through the cerebral circulation. Cerebral
vascular resistance is approximately 3–6 times greater than PVRI, and therefore selective
pulmonary vasodilator therapy has a less significant effect on total pulmonary blood flow.
Prior data on the ability of inhaled nitric oxide to improve pulmonary blood flow in the stage
II circulation are conflicting.[19,20] Our data show improved pulmonary blood flow
demonstrated by lowered CO2 (no ventilator changes were made during the sildenafil
infusion). Using Fick calculations pulmonary blood flow was improved in the subset of
subjects with baseline PVRI >2 WU x m2. Furthermore, improvement in pulmonary blood
flow was closely correlated with baseline PVRI and with change in PVRI. These data
indicate that PVR manipulation can improve pulmonary blood flow after stage II palliation.
However the actual clinical impact is directly related to the severity of pulmonary vascular
disease. We saw clinically significant improvement in saturations in those with more
markedly elevated baseline PVR. In 1 study patient with a baseline PVRI of 7.9 WU x m2, a
32% improvement in PVRI was associated with a 16% improvement in saturations.
Improvement in saturations was less clinically meaningful in the subset of patients with
PVR closer to normal.
It should be noted that in the stage II circulation pulmonary blood flow is related to the
interplay between total resistance to pulmonary blood flow (PVR + cerebral vascular
resistance) and systemic vascular resistance. Although not statistically significant, we did
see a trend towards decreased systemic vascular resistance after sildenafil administration and
this may have affected pulmonary blood flow by redistributing flow to the lower extremities.
This effect has been well demonstrated with infusion of enalaprilat in stage II subjects.[21]
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It should also be noted that these data represent acute response. An unmeasured and
theoretical longer term benefit of sildenafil may be the potential for remodeling of the
pulmonary vascular bed. Remodeling has been demonstrated in animal models where
sildenafil has been shown to attenuate pulmonary hypertension induced muscularization of
the pulmonary arteries.[22]
Although the effect on pulmonary hemodynamics was beneficial, the present study did not
demonstrate any evidence of improvement in myocardial performance. There is mounting
evidence to suggest that sildenafil may be a useful therapeutic agent in patients with cardiac
myopathy.[10] This novel application arises from data indicating increased PDE-5
expression in the hypertrophied or myopathic myocardium, including 1 study with autopsy
evidence from a single-ventricle patient.[11] Animal data suggest that PDE-5 inhibition in
the hypertrophied myocardium potentiates cyclic adenosine monophosphate activity,
resulting in a direct inotropic benefit. PDE-5 inhibition has been shown to improve systolic
and diastolic performance, cardiac output, and exertional tolerance. Several recent studies
have demonstrated improved exercise parameters in single-ventricle patients after stage III
palliation, and Goldberg et al. documented improvement in the myocardial performance
index after 3-week sildenafil treatment.[23,24] The lack of response in the present study
might reflect differences in myocardial pathology in younger children prior to stage III
palliation. It is also possible that improved performance is time-dependent and requires
myocardial remodeling.
In the present study, peak sildenafil levels were seen immediately after infusion completion
(~25 minutes after start of infusion). Compared with in vitro data, peak levels were above
the threshold needed for 77% PDE-5 inhibition in 8/10 subjects with measured levels and
90% inhibition for 4/5 subjects with doses ≥0.35 mg/kg.[25] For the range of doses studied
(0.125–0.35 mg/kg), peak levels correspond to published levels seen in adults with doses of
10–25 mg IV administered over 5–25 minutes.[26,27] This is likely due to the linear
relationship between drug volume of distribution and body weight.
Des-methyl sildenafil is the active metabolite of sildenafil and has an in-vitro potency for
the PDE-5 receptor of approximately 50% of the parent drug. In our subjects the ratio of
des-methyl sildenafil to sildenafil was similar to the approximate 15–20% ratio reported in
adults after infusion. Therefore des-methyl sildenafil accounts for approximately 7–10% of
overall PDE-5 inhibition.[25–27]
Our exposure analysis is based on a small sample size. Similar to prior analyses in adults
and neonates, there was high inter-individual variability in peak sildenafil and des-methyl
sildenafil levels. For these reasons further study is needed to more accurately define the
most appropriate dosing range in this patient population. To this end, these pharmacokinetic
data are being combined with data from other single ventricle patients to build an integrated
population pharmacokinetic model.
Overall, sildenafil was well tolerated in this small cohort of patients with no reported
adverse events. Although there was transient blood pressure lowering in the highest dosing
group, no subject demonstrated clinically significant lowering or met pre-specified criteria
for slowing or stopping of sildenafil infusion. All subjects demonstrated rapid recovery (<5
minutes after infusion completion) of blood pressure to pre-infusion levels. Generally,
sildenafil is considered to have a wide acute safety margin. In adults, peak sildenafil
concentrations up to1800 ng/mL have been well tolerated.[28] Transient blood pressure
lowering has been described in neonates with rapid infusions (<5 minutes) and in children
receiving higher infusion doses (0.66 mg/kg) after cardiopulmonary bypass.[29,30]
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Although sildenafil is acutely well tolerated, recent data from the STARTS trial have raised
concerns regarding long-term, high-dose therapy. In the STARTS trial, children with
pulmonary arterial hypertension randomized to moderate- or high-dose sildenafil therapy
(40 mg or 80 mg orally 3 times daily) demonstrated increased 3-year mortality when
compared with lower dosing regimens.[27] The STARTS trial also did not meet its primary
efficacy end point.[15] These data led to a recent U.S. Food and Drug Administration safety
advisory recommending “against sildenafil treatment for pulmonary arterial hypertension in
children.”[31] It should be noted that the European Medicines Agency also reviewed the
STARTS data but determined that “the data support the use of sildenafil in children.”[32]
The uncertainties stemming from these discrepant recommendations highlight the
importance of population-specific studies such as the present study to evaluate potential
efficacy and to optimize dosing for future larger-scale clinical trials.
There are several limitations to the present study. The study was an open-label study and did
not use a placebo group. The open-label design was necessary to allow dose escalation in the
safest manner possible, and we chose not to use a placebo group as there is inherent
difficulty recruiting adequate patients for an interventional study of this nature. Although
study investigators were not blinded, most of the outcome measures were relatively
objective with little room for interpretability. The echocardiographic measures are the
exception as these measures are subjective. While echocardiographic interpretations were
performed remotely and the interpreting physicians did not specifically know the treatment,
they did have access to the study time and, with effort, could have determined treatment
level. However bias in interpretation would more likely result in a positive study and our
echocardiographic results were negative suggesting that the readers were unbiased. There
are also inherent difficulties involved in estimating pulmonary and systemic blood flow in
the complex stage II circulation and these difficulties will affect calculation of resistance
indices. For these reasons the absolute numbers are less important than the relative values.
Saturation and pressure data were always recorded from the same location before and after
sildenafil administration to ensure that changes represent true change rather than sampling
error. While there is also likely error when estimating oxygen consumption, every subject
served as his or her own control. Any error in calculations would be present at baseline and
after therapy and therefore would not affect assessment of response. The echocardiographic
measures are limited by echocardiographic windows, especially in patients with previous
sternotomy, and by the limited validation data in complex single-ventricle populations.
Additionally, all validated non-invasive measurements of cardiac function or myocardial
performance may be affected by loading conditions. Therefore, to limit subjectivity, we
relied on 2 independent physicians to perform all echocardiographic measurements. The
inter-rater reliability was relatively good; however, there is some inherent subjectivity for all
widely reported echocardiographic measures of myocardial performance.
CONCLUSIONS
After stage II single-ventricle palliation in this small cohort of patients, single-dose
sildenafil meaningfully lowered PVR, PA pressure, and trans-pulmonary gradient. Sildenafil
also lowered mean and diastolic blood pressure with a trend towards lowered systolic blood
pressure. Contrary to reports in older single ventricle patients with longer term
administration, sildenafil did not acutely improve myocardial performance or increase
cardiac output. Although there was no overall improvement in systemic saturation, there was
incremental benefit in those with higher baseline PVR with evidence of a clinically
meaningful effect in those with elevated baseline PVRI. Doses ≥0.35 mg/kg corresponded to
peak drug concentrations seen with standard- to high-dose ranges used in adults (10–25 mg
IV). Based on these limited data we would not advocate for routine use of sildenafil after
stage II palliation as there was no overall improvement in myocardial performance, cardiac
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index or saturations in our population. However sildenafil may be beneficial in those with
high PVRI and associated desaturation. Sildenafil may be of greater benefit after stage III
palliation when the physiologic response is less confounded by the inter-relationship
between relative pulmonary to systemic flow ratios and is also less influenced by cerebral
vascular resistance. However, hepatic dysfunction in these patients may delay drug
clearance and could affect long-term safety.
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Peak des-methyl sildenafil and sildenafil levels by dosing group. Two patients (dose = 0.125
mg/kg and 0.450 mg/kg) were not included due to inadequate sample for processing.
Estimates of % PDE-5 inhibition are based on previously published in vitro data.[23]
PDE-5, phosphodiesterase type-5.
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Subjects with higher baseline PVRI demonstrated more significant improvement in PVRI
and saturations. PVRI, pulmonary vascular resistance index; WU, Wood units.
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Table 2
Sildenafil effect on hemodynamics (n=12)
Baseline median (range) Sildenafil median (range) p
Co-oximetry
CO2 (%) 43 (38,52) 41 (35,51) 0.04
SaO2 (%) 84 (59,89) 84 (75,90) 0.08
AVO2 difference (%) 15 (7,26) 19 (11,23) 0.3
Pressures
PA pressure (mm Hg) 12 (9,20) 11 (8,21) 0.03
Atrial pressure (mm Hg) 6 (4,12) 7 (3,12) 0.12
Trans-pulmonary gradient (mm Hg) 6 (4,11) 5 (3,9) <0.01
End diastolic pressure (mm Hg) 8 (5,10) 7 (4,10) 0.2
Systolic BP (mm Hg) 78 (70,98) 73 (65,98) 0.07
Diastolic BP (mm Hg) 46 (38,58) 40 (39,50) <0.01
Mean BP (mm Hg) 61 (54,82) 58 (50,70) 0.04
Calculations
Qp (L/min/m2) 2.4 (1.4,3.6) 2.5 (1.7,3.7) 0.3
Qs (L/min/m2) 4.4 (2.2,7.4) 4.4 (3.4,6.9) 0.9
Qp:Qs 0.6 (0.2,0.7) 0.6 (0.4,0.7) 0.7
PVRI (WU x m2) 2.2 (1.6,7.9) 1.7 (1.2,5.4) <0.01
SVRI (WU x m2) 12 (8,19) 10 (8,18) 0.09
Echocardiographic assessment
Systolic function (FAC) 38 (23,49) 38.5 (24,55) 0.3
Diastolic function (E: E′) 11 (6,17) 9 (5,18) 0.6
Strain (%) −14 (−20, −5) −14 (−22,−7) 0.9
Strain rate (sec−1) −0.8 (−1.3,−4.4) −0.9 (−1.4,−0.5) 0.2
Global function (MPI) 0.4 (0.2,0.5) 0.4 (0.2,0.7) 0.4
*
Percent values represent the median percent change from baseline.
SaO2, percent oxygen saturation of hemoglobin; AVO2, difference between systemic and mixed venous saturation; PA, pulmonary arterial; BP,
blood pressure; Qp, pulmonary blood flow; Qs, systemic blood flow; PVRI, pulmonary vascular resistance index; SVRI, systemic vascular
resistance index; FAC, fractional area change; E:E′, atrioventricular valve E wave to tissue Doppler E′ wave; MPI, myocardial performance index.
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